Year-end Sale % OFF 
Abstract
Alzheimer's disease (AD) has a significant economic impact on patients, caregivers, and healthcare payers. Medicare and Medicaid were estimated to cover $205 billion for AD and other cognitive disorders in 2022. Patients' out-of-pocket expenditure was projected to be $81 billion. As for caregivers, the hours of unpaid care and the value of unpaid care reached 16,023 hours and $271,598 million in total in the US. The significant burden of illness for AD and cognitive disorders makes timely diagnosis crucial in disease management. It allows healthcare providers and patients to employ strategies earlier to slow disease progression and reduce disease burden. People living with HIV (PLWH) are at higher risk of developing AD earlier because of HIV infection. This study aimed to evaluate the cost-effectiveness of implementing annual routine cognitive assessment in PLWH aged 50.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
